Phenotypic switch of vascular smooth muscle cells (VSMCs) plays a key role in the pathogenesis of different vascular diseases, such as atherosclerosis and restenosis after coronary intervention. MicroRNAs have been identified as key regulators of VSMC biology. The miR-23b is highly expressed in VSMCs and it is involved in differentation, proliferation, and migration of several non-vascular cell types. However, the role of miR-23b in vascular disease is currently unknown. Thus, the aim of the present study was to evaluate the role of miR-23b on VSMC phenotypic switch in vitro and after vascular injury in vivo.
Introduction
Vascular smooth muscle cells (VSMCs) can undergo profound and reversible changes in phenotype in response to environmental changes. 1 In particular, the switch to the so called proliferative phenotype is characterized by a marked increase in proliferation and migration, as well as a decreased gene expression of selective VSMC markers, such as smooth muscle a-actin (ACTA2) and smooth muscle myosin heavy chain (MYH11). 2, 3 These changes have been reported in various diseases, including atherosclerosis, aortic aneurysms, and neointimal proliferation. 4 -7 In particular, even though some degree of neointimal formation is required for vascular healing after balloon injury or stent implantation, excessive VSMC proliferation is responsible for luminal narrowing, the so-called restenosis. 8, 9 Unfortunately, while currently available therapies are highly efficient in inhibiting VSMC proliferation, they also prevent re-endothelialization, bringing about the dreadful risk for stent thrombosis. For this reason, a better understanding of the biological mechanisms responsible for VSMC response to injury could disclose novel therapeutic targets allowing VSMC inhibition without affecting endothelial regeneration. MicroRNAs (miRNAs) have been involved in several cardiovascular diseases, 10 -14 since they are able to modulate the expression of several genes related to cell differentiation, proliferation, migration, and apoptosis. 15, 16 Current evidence suggests that miRNAs play a critical † C.I. and S.D.R. contributed equally to this study.
role in VSMC biology. In fact, alterations in the expression levels of several miRNAs are associated with the change from the contractile (low proliferative) phenotype of mature VSMCs to the post-injury activated synthetic (highly proliferative) phenotype. 17 , 18 We previously demonstrated that the miR-133 impairs VSMC proliferation and migration by repressing the transcription factor Sp-1 and Moesin. 19 Several other groups provided additional examples of the active involvement of miRNAs in the phenotypic switch of VSMCs in response to vascular injury. 20 -22 In this study, we have focused on the influence of miR-23b
in VSMCs' phenotypic regulation in vitro and in neointimal formation in vivo. miR-23b is part of a cluster that includes miR-23b, miR-27b, and miR-24-1. 23 The miR-23b cluster has been shown to be involved in angiogenesis as well as in cardiac ischaemia and retinal vascular development. 24, 25 Particularly, recent studies have shown that the miR-23b
cluster is highly expressed in endothelial cells (ECs), and that miR-23b and miR-27b may enhance angiogenesis by targeting the anti-angiogenic proteins Sprouty2 and Sema6A. 24, 26 Moreover, it has been shown that the miR-23b plays a critical role in a wide range of biological processes. 27 -29 Most important, a previous study revealed that the miR-23b is highly expressed in rat carotid arteries. 30 However, little is known about its effect on VSMC phenotype. Hence, the aim of the present study was to evaluate the effect of miR-23b on VSMC phenotypic switch in vitro and after vascular injury in vivo.
Methods

Cell culture, transfection, and reagents
Rat aortic smooth muscle cells (VSMCs), line A10 (ATCC), were maintained in Dulbecco's Modified Eagle Medium (DMEM, GIBCO). Primary cultures of human coronary artery smooth muscle cells (HCASMCs) were obtained from Cascade Biologics TM (Life Technologies). Rat aortic ECs were purchased from CELL applications, Inc. (San Diego, CA, USA). Adenoviruses expressing miR-23b (abbreviated as Ad-miR-23b) and green fluorescent protein (GFP; Ad-GFP) were purchased from Applied Biological Materials (ABM). The locked nucleic acid microRNA target site blockers were purchased from Exiqon.
Gene expression analysis
Mature miRNAs were quantified by real-time RT-PCR using TaqMan microRNA assays (Applied Biosystems). TaqMan Gene Expression Assays (Ambion) were used for quantification of mRNA transcripts.
Western blot analysis
Western blotting was performed by a standard protocol.
2.4
In vitro cell proliferation, migration, and apoptosis assays Proliferating VSMCs were identified by using the Click-it EdU Proliferation kit (Invitrogen). The migration of VSMCs was examined with the Boyden chamber principle. Tunel staining for apoptotic nuclei was performed using the Click-iT TUNEL Alexa Fluor 488 Imaging Assay (Invitrogen).
VSMC and EC co-culture
Co-culture experiments were performed by the Transwell assay (Corning).
Reporter assays
Forkhead box O4 (FoxO4)-3 ′ -UTR sequences were cloned into luciferase reporter constructs (OriGene Technologies) and then were co-transfected with a vector containing Renilla luciferase and separately with miR-23b or miR-23b negative control (NC) into 293 cells. Luciferase activity was measured by the dual luciferase reporter assay system (Promega).
Rat carotid artery balloon injury model
Animal procedures were performed to conform the directive 2010/63/EU of the European Parliament and approved by the Italian Ministry of Health and by Institutional Animal Care and Use Committee of Magna Graecia University. Carotid artery balloon injury was performed in male Wistar rats weighing 300-350 g (Harlan, Italy) as already described. 20 Animals were sacrificed at 3 and 14 days, and carotid arteries were fixed in formalin.
Haematoxylin and eosin and Ki-67 staining were performed on crosssections.
Morphometric analysis for neointimal lesion formation
Morphometric analysis was performed on sections stained with haematoxylineosin (H&E), using the computerized image analysis system ImageJ.
Evaluation of proliferating VSMC by Ki-67 staining
Wistar rats treated with Ad-GFP, Ad-miR-23b, or vehicle were sacrificed and carotid arteries were harvested and processed as describe above. Crosssections were stained using an antibody directed against Ki-67 (Dako).
Detection of re-endothelialization by CD31 staining
Re-endothelialization in balloon-injured arteries was evaluated on day 14 after injury using primary antibodies for the EC surface marker CD31.
Statistical analysis
All data are presented as mean + SD. Two-tailed unpaired Student's tests or ANOVA were used for comparisons between continuous variables. For more details on methods, see Supplementary material online.
Results
miR-23b expression in VSMCs in vitro and after vascular injury in vivo
We first measured the expression of the individual members of the miR-23b cluster in rat carotid arteries in resting conditions and after balloon angioplasty. Interestingly, as shown in Figure 1A , real-time RT-PCR analysis revealed that miR-23b, miR-27b, and miR-24-1 levels are significantly reduced in injured carotid arteries 3 days after balloon injury compared with uninjured vessels. However, the miR-23b showed the largest differential expression (0.23-fold; P , 0.05), compared with every other cluster member. Hence, our further experiments were focused on miR-23b. Our results showed that the expression of miR-23b was significantly reduced over the time course with the lowest levels measured at day 7, followed by a slow increase over longer times ( Figure 1B) . We next examined the levels of miR-23b in cultured, phenotypically modulated, rat VSMCs in response to serum deprivation. As shown in Figure 1C , serum-starved adult rat aortic VSMCs showed a significant increase in the expression levels of miR-23b. Taken together, these results inversely link miR-23b levels to the proliferative status, hence suggesting that it could be involved with VSMC phenotypic switch in vitro and in vivo.
miR-23b modulates VSMC growth and migration in vitro
To investigate whether the miR-23b plays a relevant role in the regulation of VSMC proliferation and migration, we transiently transfected the rat VSMCs line A10 with the mature miR-23b Mimic or the mimic NC. As determined by the growth curve and the EDU incorporation assay, overexpression of miR-23b in VSMCs caused a significant decrease in the amount of proliferating cells (Figure 2A and B Figure 2C and D) . Furthermore, to evaluate the effect of miR-23b on VSMC migration, we performed a transwell migration assay. Interestingly, overexpression of miR-23b in VSMCs reduced VSMC migration by 49% compared with control cells ( Figure 2E and F), whereas the functional inhibition of miR-23b significantly increased the number of migrated cells in the lower chamber by 51% ( Figure 2G and H ). As shown in the Supplementary material online, Figure S1A -C, a similar inhibitory effect of miR-23b on proliferation and migration was also observed in HCASMCs. Of note, miR-23b overexpression did not show a significant effect on apoptosis in VSMCs (see Supplementary material online, Figure S2A ). These in vitro observations reveal that the miR-23b is a critical regulator of VSMC proliferation and migration.
miR-23b regulates smooth muscle marker gene expression in vitro
The passage of VSMCs from a differentiated to the dedifferentiated phenotype is characterized by a markedly reduced expression of smooth muscle marker genes such as ACTA2 and MYH11. 4, 31 Given the inhibitory effect of miR-23b on VSMC proliferation and migration observed in the previous experiments, we hypothesized that miR-23b may act, at least in part, through the induction of smooth muscle marker genes. To test this hypothesis and confirm the previous results, cultured VSMCs were transfected with either miR-23b Mimic or the miR-23b Inhibitor. As shown in Figure 3A , miR-23b overexpression and inhibition were respectively responsible for up-and downregulation of ACTA2 and MYH11 mRNA levels. Consistent with these findings, expression of both ACTA2 and MYH11 proteins in VSMCs was significantly increased (1.46-and 1.69-fold, respectively; P , 0.05) upon treatment with miR-23b Mimic, and was significantly decreased (0.45-and 0.33-fold, respectively; P , 0.05) upon transfection with Figure 1 miR-23b expression in VSMCs in vitro and after vascular injury in vivo. miR-23b levels were normalized to U6 levels. (A) miR-23b, miR-27b, and miR-24-1 levels in uninjured and injured rat carotid arteries, as determined by qRT-PCR at 3 days after injury (*P , 0.05 vs. uninjured vessel, n ¼ 6).
(B) miR-23b levels in uninjured and injured rat carotid arteries at 3, 7, 14, and 28 days after injury (*P , 0.05, n ¼ 4). (C) miR-23b levels detected by qPCR in serum-starved VSMC (*P , 0.01 vs. proliferating cells, n ¼ 4).
the miR-23b Inhibitor ( Figure 3B and C ). It is well established that Myocardin (Myocd) is a primary component of the molecular regulatory network that modulates VSMC phenotypic switch. In particular,
Myocd interacts with the serum response factor (SRF) to activate the transcription of several VSMC genes, as the differentiation markers ACTA2 and MYH11. 1 To further investigate the effect of miR-23b on Role of miR-23b in vascular smooth muscle cells marker gene expression, VSMCs were transiently transfected with the miR-23b Mimic, the miR-23 Inhibitor, the mimic NC, or with the Inhibitor NC, and total RNA was harvested to measure Myocd expression by qPCR. Notably, treatment of VSMCs with the miR-23b Mimic caused a 2.5-fold induction of Myocd, whereas the transfection with the miR-23b Inhibitor significantly reduced Myocd levels (see Supplementary material online, Figure S2B ). Taken together, these data suggest that endogenous miR-23b is correlated with the expression of VSMC marker genes.
miR-23b overexpression reduces neointimal hyperplasia in rat carotid arteries after balloon injury in vivo
To examine the role of miR-23b in neointima formation, we used a wellestablished and reproducible balloon injury model of the rat carotid artery, as previously described. 32 Briefly, rat carotid arteries were transduced with either Ad-miR-23b [10 10 plaque forming units (pfu/mL), Ad-GFP (10 10 pfu/mL), or just incubated with phosphate-buffered saline (CTRL)]. As shown in Figure 4A , infection with Ad-miR-23b was responsible for a 19-fold increase (P , 0.01) in miR-23b levels 3 days after balloon injury. Western blots also showed an increased expression of GFP in injured carotids transduced with viral particles (see Supplementary material online, Figure S3 ). Since previous studies found that smooth muscle marker genes are reduced in response to vascular injury, we tested the effect of the administration of the Ad-miR-23b on these genes, observing an increase in the expression of the smooth muscle marker genes ACTA2 and MYH11 (2.2-and 3.6-fold, respectively; P , 0.01 for both). Similarly, RNA analysis further demonstrated that overexpression of miR-23b enhanced the expression of Myocd (1.8-fold; P , 0.01) after vessel injury ( Figure 4B ). Next, we evaluated the role of miR-23b in regulating VSMC proliferation in response to arterial injury by Ki-67 staining. Figure 4C shows representative Ki-67-stained cross-sections of the left carotid artery from a saline-treated rat, an Ad-GFP-treated rat, and an Ad-miR-23b-treated rat, 3 days after balloon injury. In the injured artery exposed to saline or Ad-GFP, Ki-67-positive nuclei were observed in some cells of medial layer (proliferation index ¼ 26 + 6%; P , 0.05). However, a significant decrease (proliferation index ¼ 12 + 3.5%; P , 0.05) of Ki-67-positive cells was observed in the injured arterial wall of rats treated with Ad-miR-23b ( Figure 4D) .
Finally, we studied the effect of adenovirus-mediated expression of miR-23b on balloon injury-induced neointimal formation. As shown in Figure 5A -C, 14 days after balloon injury, a thick neointima was evident in carotid arteries of rats treated with saline or Ad-miR-GFP. Importantly, Ad-miR-23b caused a significant reduction in both neointima/ media ratio and neointimal area (neointimal area ¼ 0.123 + 0.026 mm and neointima/media ratio ¼ 0.645 + 0.134) compared with the CTRL (Figure 5B and C ) . Altogether, our data show that the overexpression of miR-23b reduces the phenotypic modulation of VSMCs in vivo. These findings are consistent with the previously observed decrease in miR-23b levels in injured arteries and suggest that this miRNA plays an important role in VSMC response to vessel injury. Role of miR-23b in vascular smooth muscle cells
Molecular targets of miR-23b in VSMC phenotypic switch
It has been shown that a single miRNA can affect the expression of a large number of protein-coding genes to regulate multiple cellular events. 33, 34 We used the online tool TargetScan to search for potential targets of the miR-23b, and identified the transcription factor FoxO4. Furthermore, we focused our attention on two known targets of miR-23b, urokinase-type plasminogen activator (uPA) and SMAD family member 3 (SMAD3), for their role in modulating VSMC phenotypic switch after vascular injury. 35 -38 As shown in Figure 6A and B, infection with the Ad-miR-23b significantly inhibited protein expression of FoxO4, SMAD3, and uPA (0.23 + 0.07-, 0.32 + 0.06-, and 0.34 + 0.08-fold, respectively) in the injured arterial wall compared with the CTRL. Also, direct transfection of cultured VSMCs with the miR-23b Mimic resulted in decreased expression of FoxO4, uPA, and SMAD3, whereas the opposite effect was obtained with the miR-23b Inhibitor ( Figure 6C and D) . To determine whether FoxO4 is a direct target of miR-23b, we cloned the 3 ′ -UTR of FoxO4 into a luciferase reporter construct and evaluated luciferase activity in 293 cells transfected upon chase with miR-23b Mimic. Interestingly, miR-23b significantly repressed luciferase activity on the reporter construct with the FoxO4 3 ′ -UTR ( Figure 6E ). It is known that FoxO4 acts as an activator of VSMC migration in response to TNF-a. 39 TNF-a is an inflammatory cytokine, which presents at sites of vascular injury and plays a role in VSMC phenotypic switch. 40, 41 Hence, we analyzed the influence of the miR-23b on FoxO4 protein expression in TNF-a-stimulated VSMCs. Western blot analysis of VSMCs treated with TNF-a (100 ng/mL) revealed a 2.5-fold induction of FoxO4 ( Figure 7A) . Notably, functional inhibition of miR-23b directly amplified TNF-a (100 ng/mL) induced FoxO4 expression, whereas transfection with the miR-23b Mimic inverted this phenomenon ( Figure 7B) , showing a significant reduction of TNF-a-induced FoxO4 protein levels. We finally investigated the effect of miR-23b on VSMC migration in response to TNF-a, by the transwell migration assay. The migratory effect of TNF-a was significantly reduced through overexpression of the miR-23b. On the contrary, miR-23b inhibition enhanced TNF-a-induced VSMC migration ( Figure 7C and D) . In addition, to further confirm the involvement of FoxO4 in mediating the above reported effects exerted by miR-23b on VSMCs, in another set of experiments we used specific target site blockers directed to the Role of miR-23b in vascular smooth muscle cells Figure S5A ). Consistently, while the treatment with the miR-23b Mimic reduced VSMC migration, this effect was partly, yet significantly, prevented when the migration assay was repeated in the presence of the specific TBS FoxO4 (see Supplementary material online, Figure S5C ), demonstrating that binding of miR-23b to the 3 ′ -UTR of the FoxO4 gene is important to mediate miR-23b effects on VSMC migration. On the contrary, treatment with the TBS FoxO4 had no significant effect on miR-23-induced VSMC proliferation (see Supplementary material online, Figure 5B ). Furthermore, since it is known that FoxO4 regulates TNF-a-induced VSMC migration by activating MMP-9 gene transcription, 39 we analyzed MMP-9 expression in VSMCs transfected with miR-23b Mimic. Notably, overexpression of miR-23b Mimic reduced the levels of MMP-9 in TNF-a-treated VSMCs (see Supplementary material online, Figure S6 ). 
Discussion
The major findings of the present study are that: (i) miR-23b is downregulated in arteries after vascular injury and its overexpression in vivo inhibits neointimal formation; (ii) miR-23b-dependent inhibition of VSMC proliferation and migration seemingly mediates this phenomenon, as also confirmed by the inverse relationship between miR-23b expression and the levels of classical VSMC markers, such as ACTA2 and MYH11; (iii) the effect of miR-23b on VSMCs is mediated, at least in part, by its targets SMAD3, uPA, and FoxO4, key regulators of VSMC physiology. Differentiated VSMCs retain significant plasticity even in adult animals. In fact, VSMCs can undergo a phenotypic change from a quiescent to a synthetic phenotype in response to physiological and pathological stimuli. 1 This process is characterized by increased proliferation and migration and decreased expression of VSMC differentiation marker genes. 4, 31 Phenotypic modulation of VSMCs is crucial in various vascular disorders, such as atherosclerosis or neointimal lesion formation after stent implantation.
9,42
A growing body of evidence suggests that miRNAs play a critical role in the phenotypic switch of VSMCs in vascular disease. 21, 43, 44 miR-23b is expressed together with miR-27b and miR-24-1 from a unique primary transcript. 23 It has been documented that the miR-23b plays an important role in cancer. 27, 45 For example, recent studies revealed that miR-23b levels are reduced in human prostate tumour samples, and are inversely correlated with the amount of cell proliferation and migration. 46 In addition, miR-23b interferes with the pathogenesis of multiple autoimmune diseases by targeting pro-inflammatory cytokine-mediated signalling. 47 
Effects of miR-23b on VSMC phenotypic switch
miRNA expression patterns exhibit a dynamic profile in the vessel wall in response to injury. Despite a deregulation of miR-23b has been observed after injury, it was not clear whether this change is a cause or consequence of the pathological context. Interestingly, we confirmed the previous observation that miR-23b is down-regulated in the vascular wall after angioplasty. Moreover, we showed that miR-23b expression is strongly induced in VSMCs in response to serum withdrawal. More importantly, we demonstrated that the function of endogenous miR-23b is positively correlated with the expression levels of Myocd and VSMC genes. In other words, miR-23b levels are inversely correlated with the VSMC differentiation status. Arterial response to injury typically involves VSMC proliferation and migration from the media to the intima with consequent neointima growth and luminal narrowing. In the present study, we showed that overexpression or inhibition of endogenous miR-23b, respectively, inhibits or promotes VSMC proliferation and migration, confirming the key role played by miR-23b in the modulation of VSMC phenotype. Consistent with the inhibitory effect of miR-23b on VSMC proliferation, we found a lower quantity of Ki-67-positive nuclei in the media of Ad-miR-23b-treated arteries after balloon injury. Moreover, miR-23b overexpression limited neointimal hyperplasia in carotid arteries after balloon injury. On the other hand, the treatment with the AntagomiR-23b did not significantly affect neointima formation after balloon injury. A possible explanation for this finding is that the expression levels of endogenous miR-23b are already very low in injured arteries, so that it is very improbable that any further reduction had a significant impact on neointima. Altogether, these results highlight the key role of endogenous miR-23b
in vascular smooth cells (VSMCs). In fact, the findings observed after the experimental modulation of miR-23b levels represent an important confirmation that the observed variations in the endogenous levels in different pathophysiological conditions are indeed related to the role of active partaker played by the miR-23b rather than an indirect marker of other biological phenomena underlying the cellular effects object of study.
miR-23b targets and molecular mechanism
Notably, previous studies have shown that miR-23b has several targets that might be involved in modulating its effects on VSMCs. Among the known targets of miR-23b, uPA and SMAD3 are particularly interesting. uPA is a key regulator of neointimal growth and vascular remodelling. In fact, previous studies demonstrated that increased uPA expression contributes to VSMC proliferation, migration, and neointima formation after injury. 48 -50 Moreover, Menshikov et al. 35 reported that autocrine uPA production can be responsible for the induction of VSMC proliferation. SMAD3 is involved in the TGF-b signalling pathway. Its overexpression was described in several vascular diseases, including neointimal formation following vascular surgery. 51 Interestingly, a recent study reported that overexpression of SMAD3 stimulates VSMC proliferation and neointimal formation in rat in carotid arteries after balloon injury. 37 In the present study, we showed for the first time that miR-23b overexpression suppresses uPA and SMAD3 in carotid arteries after balloon injury. In line with these findings, we also demonstrated that uPA and SMAD3 levels were decreased in VSMCs after transfection with the miR-23b Mimic, whereas the opposite effect was obtained with the miR-23b Inhibitor. Altogether, these observations suggest that miR-23b regulates VSMC biology at least in part by directly targeting uPA and SMAD3. We further identified FoxO4 as a target of miR-23b. FoxO4 is a member of the transcription factor Forkhead box O (FoxO) family that acts as a repressor of smooth muscle differentiation genes and as an activator of VSMC migration. 39, 52, 53 Liu et al. 52 reported that nuclear FoxO4 expression is up-regulated in proliferating VSMCs from the vascular neointima of the carotid artery following injury in vivo, suggesting its involvement in the phenotypic switch of VSMCs. Of note, knockdown of the constitutively expressed FoxO4 prevents neointimal formation in an animal model of restenosis. 39 We showed through gain-of-function and loss-of function approaches that FoxO4 mRNA is a direct target of miR-23b in VSMCs. In fact, our experiments demonstrated that miR-23b is sufficient to regulate FoxO4 expression in cultured VSMCs. We confirmed direct targeting of FoxO4 by the miR-23b through experiments with a luciferase reporter construct with the 3 ′ -UTR of the FoxO4 gene, and using specific target site blockers directed to the binding/target site of miR-23b on the FoxO4 3 ′ -UTR (TSB FoxO4 ). This mechanism was further verified in vivo in rat carotid arteries after angioplasty. These results are particularly interesting, since they might explain our finding that the miR-23b modulates the expression levels of several key partakers of VSMC phenotypic modulators, such as Myocd and MMP-9. In fact, it was previously reported that FoxO4 reduces the expression of VSMC-specific genes, at least in part, by interacting with Myocd, a SRF-dependent co-activator for smooth muscle differentiation. 52 FoxO4 can also negatively regulate Myocd expression in human aortic smooth muscle cells. 54 Consistent
with these findings, we demonstrated that Myocd expression is up-regulated in Ad-miR-23b-treated injuried arteries. Since Myocd is a key modulator of the gene expression of specific differentiation markers of VSMCs, 19 it is tempting to speculate that miR-23b-induced up-regulation of differentiation markers in VSMCs might be also partly mediated by the downstream molecule FoxO4. In fact, it is known that FoxO4 binds to Myocd in the nucleus. However, the FoxO4/Myocd complex is dissociated upon activation of the Akt signalling, which makes both FoxO4 and Myocd able to exert their regulatory role. In particular, this latter is a potent transcription activator, that when complexed with SRF, induces the expression of VSMC marker genes. In fact, while miR-23b targets FoxO4 reducing its expression levels, this reduction in FoxO4 levels partially releases the physiological repression it exerts on ACTA2 and MYH11, with the net effect of an increase in the expression levels of these latter molecules. This hypothesis confirmed findings of the present study that blockade of the 3 ′ -UTR specific target site blockers (TSB FoxO4 ) prevents a miR-23b-induced increase in the expression of ACTA2 and MYH11. It is known that FoxO4 is able to increase MMP-9 expression promoting VSMC migration in response to TNF-a. 39 In the present study, we observed that miR-23b prevents the up-regulation of both MMP-9 and FoxO4 levels, together with the TNF-a-induced VSMC migration. Taken together, these data provide novel insights into the mechanisms by which down-regulation of miR-23b after vascular injury may contribute to the phenotypic switching of VSMCs. Interestingly, it was recently shown that also Myocd is a regulator of VSMC migration. 55 In fact, it causes inhibition of the PDGF-RB pathway in response to vascular injury, through induction of miR-24 and miR-29a. Combining these observations with our results, we hypothesized that concomitant reduction in the expression of members of the miR-23b cluster after vascular injury plays a pivotal role in VSMC phenotypic switch. In other words, the intriguing hypothesis is that the entire cluster regulates several aspects of the same biological process in an integrative manner. The biological relevance of the miR-23b-miR27b-miR-24-1 cluster is further confirmed by recent findings that their dysregulation is associated with vascular diseases, such as abdominal aortic aneurysm. 56 
Limitations of the study
Despite our results clearly demonstrate an involvement of miR-23b in vascular response to injury, the exact molecular mechanisms involved in the regulation of miR-23b expression following vascular injury remain unclear. In particular, a complex interaction between VSMCs and ECs could be present in vivo. In fact, although VSMCs are not directly exposed to blood flow-related shear stress in normal conditions, being shielded by the EC layer and the extracellular matrix, vascular injury can cause endothelial denudation, with consequent direct exposition of the superficial VSMC layer. However, in this respect, we did not identified a direct miR-23b-mediated EC -VSMC interaction in our model. In fact, when VSMCs were co-cultured with ECs transfected with the miR-23b Inhibitor, we did not found any effect on VSMC proliferation or on the expression levels of specific differentiation markers. Secondly, since miRNAs modulate biological functions via multiple target mRNAs, we do not exclude the possibility that other miR-23b targets are concurrently involved in VSMC phenotypic switch.
Conclusions
The results of the present study demonstrate for the first time that miR-23b is a key regulator of the phenotypic switch in VSMCs in vitro and its overexpression inhibits neointimal formation after vascular injury in vivo. These results might have important clinical implications to pave the way for the development of novel, more selective and efficient strategies to prevent restenosis after vascular interventions.
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